MTOR and neoplasm: Upregulation of the mammalian target of rapamycin (mTOR) is often observed in BTCs; however, metformin can directly activate the AMP-activated protein kinase (AMPK) signaling pathway, leading to inhibition of the mTOR signaling pathway, thereby downregulating protein synthesis, cell proliferation, and tumor angiogenesis [51,52,53].